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AbsTrACT
Objective to evaluate changes in left ventricular 
diastolic function (lVDF) parameters and their associated 
risk factors over a period of 11 years among community-
dwelling women and men.
Methods echocardiography was performed three 
times among 870 women and 630 men (age 67±3 
years) from the prospective population-based rotterdam 
study during a period of 11-year follow-up. changes in 
six continuous lVDF parameters were correlated with 
cardiovascular risk factors using a linear-mixed effect 
model (lMM).
results in women, smoking was associated with 
deleterious longitudinal changes in deceleration time 
(Dt) (Beta (β): 7.73; 95% ci 2.56 to 12.9) and high-
density lipoprotein cholesterol was associated with 
improvement of septal e’ (β: 0.37; 95% ci 0.13 to 
0.62) and e/e’ ratio (β: −0.46; 95% ci −0.84 to –0.08) 
trajectories. among men, diabetes was associated with 
deleterious longitudinal changes in a wave (β: 3.83; 
95% ci 0.06 to 7.60), septal e’ (β: −0.40; 95% ci −0.70 
to –0.09) and e/e’ ratio (β: 0.60; 95% ci 0.14 to 1.06) 
and body mass index was associated with deleterious 
longitudinal changes in a wave (β: 1.25; 95% ci 0.84 to 
1.66), e/a ratio (β: −0.007; 95% ci −0.01 to –0.003), 
Dt (β: 0.86; 95% ci 0.017 to 1.71) and e/e’ ratio (β: 
0.12; 95% ci 0.06 to 0.19).
Conclusions smoking among women and metabolic 
factors (diabetes mellitus and body mass index) among 
men showed larger deleterious associations with 
longitudinal changes in lVDF parameters. the favourable 
association of hDl was mainly observed among women. 
this study, for the first time, evaluates risk factors 
associated with changes over time in continuous lVDF 
parameters among women and men and generates new 
hypothesis for further medical research.
InTrOduCTIOn
Left ventricular diastolic dysfunction is highly prev-
alent and worsen with advancing age.1–3 Persistence 
or progression of diastolic dysfunction is a risk 
factor for heart failure (HF) among the elderly.2 
Recent data suggest that diastolic dysfunction is 
present in the majority, around 70% of patients 
with heart failure with preserved ejection frac-
tion (HFpEF).4 Although plenty of evidence-based 
treatments for heart failure with reduced ejection 
fraction exist, there is no treatment with proven 
benefits for HFpEF.5 
Impairment of left ventricular diastolic function 
(LVDF) occurs gradually and has been shown to be, 
at least partly, reversible.1 6 Therefore, early detec-
tion of subclinical impairment in LVDF and identi-
fication and treatment of its associated risk factors 
to prevent or slow the progression to overt HF is 
important. To date, several risk factors associated 
with LVDF have been identified.7 8 However, longi-
tudinal studies evaluating changes in continuous 
LVDF parameters over time in a general population 
of subjects without clinically diagnosed HF are scant 
and have been mostly performed among middle-
aged individuals. As the occurrence of various HF 
phenotypes differs between women and men,5 it has 
been suggested that gender differences in suscep-
tibility to risk factors might partly explain these 
dissimilarities.6 However, recent studies have failed 
to address gender differences in the set of changes 
in LVDF and its associated risk factors.4–7 Notably, 
while women tend to have a better LVDF until 60 
years of age, gender disparities are reversed after 
the menopause.5 To further clarify sex differences 
in the pathophysiology of diastolic dysfunction, 
studying changes in continuous LVDF parameters 
among women and men and their correlates, espe-
cially at older ages, is warranted.
We, therefore, aimed to evaluate longitudinal 
changes in continuous LVDF parameters during 11 
years of follow-up among women and men from a 
large prospective population-based cohort.9 Partic-
ipants were all free from clinically diagnosed HF 
at the time of echocardiographic examinations and 
during follow-up. In addition, we investigated the 
risk factors associated with the changes in LVDF 
parameters among women and men.
MeTHOds
study population
The Rotterdam Study (RS) is a prospective popu-
lation-based cohort that included participants aged 
≥55 years in the district of Ommoord, Rotterdam, 
The Netherlands.9 The study started in 1990 with 
7983 participants (RS-I) and was extended twice: in 
2000 (RS-II, n=3014) and 2006 (RS-III, n=3932). 
The follow-up examinations take place every 3–4 
years. The RS was approved by the Medical Ethics 
Committee according to the Population Study Act 
Rotterdam Study. All participants provided written 
informed consent.
The present study used data for six LVDF echo-
cardiographic parameters from the fourth, fifth and 
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sixth examinations of the first cohort (RS-I) and the second, 
third and fourth examinations of the second cohort (RS-II). Out 
of the six LVDF parameters under study, three repeated echo-
cardiographic measurements were available for four indexes 
among 1869 participants. We excluded 369 individuals due to 
poor echocardiographic images, atrial fibrillation, artificial pace-
maker, moderate–severe valve compromise and clinically diag-
nosed HF at the time of echocardiographic examinations and 
during the follow-up. Therefore, we included a total of 1500 
participants (630 men and 870 women) (figure 1). For two 
LVDF parameters, two repeated measurements were available in 
a total of 1528 (646 men and 882 women) subjects from the fifth 
and sixth examinations of the first cohort (RS-I) and the third 
and fourth examinations of the second cohort (RS-II) (online 
supplementary figure 1).
LVdF parameters
We studied six continuous LVDF parameters: the early transmi-
tral ventricular diastolic filling velocity (E wave), late diastolic 
filling velocity (A wave) and the early diastolic longitudinal 
filling velocity of the septal mitral annulus (septal e’) during 
three cardiac cycles. The means of the E wave, A wave and septal 
e’ were used to calculate E/A and E/e’ ratios. Mitral valve decel-
eration time (DT) was measured as the time between the peak 
E-top wave and the upper deceleration slope extrapolated to the 
zero baseline using a continuous wave Doppler.10 11 Additional 
information on echocardiographic measurements is provided in 
the online-supplementary material.
Assessment of cardiovascular risk factors
The detailed information regarding the evaluation of cardiovas-
cular risk factors is given in the online supplementary material.
sTATIsTICAL AnALysIs
In the descriptive analysis, continuous variables with normal 
distribution were reported as mean (SD) and categorical vari-
ables as numbers (percentages). We compared the mean and 
percentage values for women and men using t-test and z-pro-
portion tests, respectively. Longitudinal changes in LVDF 
parameters over time were plotted, treating age as a time-
varying covariate. For each of the six parameters, a longitu-
dinal data analysis using an LLM was performed. The outcome 
of interest in each model was the two or three repeated 
measurements for each index as a continuous variable. Age (as 
a time-varying covariate), systolic and diastolic blood pressure 
(SBP, DBP), heart rate (HR), total and high-density lipopro-
tein (HDL) cholesterol, blood pressure-lowering medication, 
lipid-lowering medication (LLM), diabetes mellitus (DM), 
current smoking, coronary heart disease (CHD), left ventric-
ular mass (LVM) indexed by body surface area, left ventricular 
ejection fraction (LVEF), physical activity, left atrial diam-
eter (LAD) and cohort were included in the fixed part of all 
models. The random part of the models only included age (as 
a time-varying covariate). All analyses were performed in total 
population and women and men separately. We checked for 
possible interaction between sex and different covariates in the 
total population. We additionally checked for the interaction 
terms between age, as a time-varying, and all covariates. We 
also compared the characteristics of the included participants 
with those who did not return for the follow-up echocardi-
ography examinations. For more details regarding the anal-
yses, consult the online supplementary material. The analyses 
were performed with R V.3.2.5 (R Foundation for Statistical 
Computing, Vienna, Austria), and STATA V.14.0 (Stata Corp, 
College Station, TX). A two-sided p value of <0.05 was 
considered statistically significant. Additionally, we considered 
Figure 1 Flowchart for the participants included in the analysis of longitudinal changes in LVDF parameters measured 3 times over 11 years of 
follow-up. AF, atrial fibrillation; LVDF, left ventricular diastolic function.
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a more conservative Bonferroni-corrected p value of <0.0083 
(=0.05/6, considering six LVDF parameters).
resuLTs
Table 1 details the baseline characteristics of 870 women and 
630 men for the analyses of E wave, A wave, E/A ratio and DT, 
in whom three repeated measurements were available during 
11.1 years of follow-up. Women had higher HR, total and HDL 
cholesterol, LAD and ejection fraction. Men had larger DBP, 
LVM, left ventricular end-diastolic diameter (LVEDD), and left 
ventricular end-systolic diameter (LVESD) and CHD prevalence. 
For septal e’ and E/e’ ratio, two repeated measurements were 
available among 882 women and 646 men during 4.2 years of 
follow-up (online supplementary table 1).
Longitudinal changes in LVdF among women and men
Longitudinal changes in LVDF parameters were plotted against 
age (as a time-varying covariate), based on univariate models. 
The shapes of the longitudinal changes in all six LVDF parame-
ters over time were similar in women and men (figure 2). There 
was no interaction between age (as a time-varying covariate) 
and sex. The plots revealed a progressive deleterious mono-di-
rectional change in the longitudinal trajectories of all six LVDF 
parameters over time; that is, a gradual rise in E wave, A wave, 
DT and E/e´ ratio values and a gradual decline in E/A ratio and 
septal e’. Despite similar trends in LVDF changes in both sexes, 
there were statistically significant differences in the mean values, 
with overall poorer indexes in women. The online supplemen-
tary table 2 presents detailed information on cross-sectional 
values for LVDF parameters per age and gender category.
risk factors associated with longitudinal changes in LVdF
As E wave, A wave, DT and E/e´ ratio values progressively, 
and deleteriously, raised over time, a positive beta coefficient 
for a risk factor means that the risk factor was associated with 
an increment in the trajectory of these LVDF parameters over 
time. On the contrary, a negative beta coefficient means that 
the risk factor was associated with a decrement in the trajectory 
of these LVDF parameters over time. Therefore, a positive risk 
factor coefficient is associated with an unfavourable progression 
and a negative risk factor coefficient into a favourable progres-
sion on LVDF parameters over time. E/A ratio and septal e’ values 
progressively, and deleteriously, diminish over time. Therefore, 
a negative beta coefficient for a risk factor means that the risk 
factors were associated with decrement and a positive coefficient 
means that the risk factor was associated with an increment in 
the trajectory of these LVDF parameters over time. Therefore, a 
positive coefficient translates into a favourable progression and 
a negative coefficient into an unfavourable progression on LVDF 
parameters over time.
Tables 2 and 3 show all beta coefficients and CIs of different 
risk factors with longitudinal changes in LVDF indexes over time 
among women and men. Online supplementary tables 3 and 4 
show the summary of the risk factors significantly associated with 
Table 1 Baseline clinical and echocardiographic characteristics of the participants
Women (n=870) Men (n=630) P  value*
Clinical features
  Age, years 67.30 (4.95) 67.29 (4.91) 0.980
  BMI, kg/m² 27.42 (4.07) 27.08 (2.94) 0.069
  SBP, mm Hg 144.40 (18.32) 143.92 (19.20) 0.626
  DBP, mm Hg 79.84 (10.11) 82.01 (9.90) <0.001
  Blood pressure-lowering medication, n (%) 261 (30.0) 208 (33.0) 0.2130
  Hypertension, n (%) 609 (70.0) 446 (70.8) 0.7378
  Heart rate, beats/min 69.36 (9.70) 65.79 (10.55) <0.001
  Total cholesterol, mmol/L 5.96 (0.94) 5.45 (0.93) <0.001
  HDL cholesterol, mmol/L 1.60 (0.40) 1.31 (0.31) <0.001
  Lipid-lowering medication, n (%) 174 (20.0) 130 (20.63) 0.765
  Current smoker, n (%) 106 (12.2) 58 (9.2) 0.069
  Prevalent CHD, n (%) 16 (1.84) 61 (9.68) <0.001
  Prevalent DM, n (%) 84 (9.66) 62 (9.84) 0.908
Echocardiography features
  LVM index, g/m² 70.66 (15.47) 78.17 (18.19) <0.001
  Left atrium diameter/BSA, mm/m² 21.41 (2.69) 20.76 (2.45) <0.001
  LVEDD, mm 49.39 (4.96) 53.36 (4.86) <0.001
  LVESD, mm 30.12 (7.87) 33.66 (8.01) <0.001
  Relative wall thickness, cm 0.29 (0.06) 0.29 (0.05) 1
  Ejection fraction, % 65.87 (6.75) 63.69 (7.92) <0.001
  E wave, cm/s 67.38 (13.02) 64.48 (12.97) <0.001
  A wave, cm/s 83.33 (17.82) 76.61 (17.68) <0.001
  E/A ratio 0.83 (0.18) 0.86 (0.20) <0.001
  Deceleration time 204.4 (35.54) 209.19 (39.78) <0.001
  e`septal 6.87 (1.79) 7.29 (1.78) <0.001
  E/e`septal ratio 10.43 (2.62) 9.54 (2.51) <0.001
Values are mean (±SD) or numbers (percentages).
*P value for comparison of different characteristics between women and men.
BMI, body mass index; BSA, body surface area; CHD, coronary heart disease, DBP, diastolic blood pressure; DM, type 2 diabetes mellitus; LVEDD, left ventricle end diastolic 
dimension; LVESD, left ventricle end systolic dimension; LVM, left ventricular mass; SBP, systolic blood pressure.
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Figure 2 Plots for changes in LVDF parameters over time among women and men (red line: women, blue line: men). LVDF, left ventricular diastolic 
function.
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longitudinal changes in LVDF parameters among women and 
men. Figure 3 shows the core findings of our study, summarising 
the main differences among women and men in risk factors asso-
ciated with changes in LVDF trajectories.
e wave
Among both women and men, age and SBP were associated 
with a rise in E wave while DBP and LVM were associated with 
a decline in E wave over time. Although BMI was associated 
with a rise in E wave in both sexes, this association was only 
significant in women (tables 2 and 3 and online supplementary 
tables 3 and 4).
A wave
Age, SBP, BMI and HR were associated with a rise in A wave 
over time in both genders, and DM only in men (tables 2 and 3 
and online supplementary tables 3 and 4).
e/A ratio
Risk factors associated with a decline in E/A ratio were age, DBP 
and HR in both genders. Only in men, BMI was significantly 
associated with a decline in E/A ratio and LVEF and LAD with 
a rise in E/A ratio (tables 2 and 3 and online supplementary 
tables 3 and 4).
deceleration time
Among women, current smoking was the strongest risk factor 
significantly associated with a rise in DT over time. Age was 
associated with a rise in DT in both genders. SBP in women and 
HR in men were significantly associated with a decline in DT. 
BMI was associated with a rise in DT only in men (tables 2 and 3 
(tables 2-3 and online supplementary tables 3 and 4).
septal e’
LVM was associated with a decline in septal e’ in both genders. 
Additionally, LLM and prevalent CHD among women and DM 
among men were associated with a decline in septal e’. Among 
women, age and HDL cholesterol were also associated with 
a rise in septal e’ (tables 2 and 3 and online supplementary tables 
3 and 4).
e/e’ ratio
LVM was associated with a rise in E/e’ ratio in both genders. 
Additionally, LLM was associated with the rise and HDL choles-
terol with a decline in the E/e’ ratio among women. Among men, 
prevalent CHD, BMI and DM were associated with a rise in 
the E/e’ ratio (tables 2 and 3 and online supplementary tables 
3 and 4). P values for sex interaction in the associations of BMI 
and DM with the E/e’ ratio were significant.
dIsCussIOn
In the large prospective population-based RS, women had 
poorer diastolic function than men. However, the tendency of 
age-related changes in LVDF parameters over time was similar 
in both genders. Current smoking among women and metabolic 
factors such as BMI and DM among men were found to be asso-
ciated with deleterious progression of longitudinal changes in 
LVDF parameters over time. HDL cholesterol showed a favour-
able association with LVDF trajectories mainly in women.
Although few studies have shown the intrinsic effect of age 
and several cardiovascular risk factors on worsening of LVDF 
parameters,3 7 a comprehensive longitudinal assessment of 
continuous LVDF parameters by gender over time is scant.6 T
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Patterns of longitudinal changes in the LVDF indexes over time 
in our study indicated a progressive impaired relaxation as 
well as increasing filling pressures with advancing age in both 
genders. In line with our findings, Kuznetsova et al7 also found 
a rise in the E/e’ ratio and decline in septal e’ and E/A ratio over 
time. The LVDF parameters we reported are also comparable 
to those reported by Caballero et al12 in populations older 
than 60 years, implying a worsening of diastolic function with 
ageing.
We found that the postmenopausal women in our study 
had a worse diastolic function compared with men, providing 
more evidence regarding the larger burden of diastolic 
dysfunction among women after menopause.5 12 In younger 
men, a larger decline in most of the LVDF indexes over 
time was observed. Women have a better diastolic function 
until 60 years of age after which they experience a steeper 
decline and worse diastolic function compared with men.5 
Ageing per se seems to produce more eccentric remodelling 
and threefold larger apoptosis in men compared with women 
that might explain a steeper decline in diastolic reserve and 
the higher prevalence of diastolic dysfunction and HFpEF in 
women compared with men.13 14
Longitudinal analyses of risk factors associated with changes 
in continuous LVDF parameters over time from a gender-spe-
cific perspective are scarce. Kuznetsova et al,7 based on the 
risk factors identified in cross-sectional studies, evaluated the 
longitudinal determinants of LVDF parameters and showed 
advancing age, higher insulin levels, DBP and HR to worsen 
LVDF indexes over time. A recent longitudinal analysis of 
Framingham,15 based on categorical LVDF parameters during 
the 5.6-year follow-up, showed that age, female sex, changes 
in SBP and DBP, BMI, serum triglycerides and DM were associ-
ated with worsening diastolic function in the total population. 
Our current study expands these findings by examining the risk 
factors associated with changes in various continuous LVDF 
parameters over 11 years of follow-up from a gender-specific 
perspective. The main advantage of analysing the continuous 
LVDF parameters is a greater power to detect associations and 
a lower misclassification bias than analysis based on categorical 
classification.16
AssOCIATIOn OF rIsk FACTOrs WITH LOngITudInAL 
CHAnges In LVdF PArAMeTers AMOng WOMen And 
Men
blood pressure
SBP and DBP showed significant associations with longitudinal 
changes in E wave, A wave and E/A ratio among women and 
men. The opposite direction of the effect for SBP and DBP 
suggested the effect of pulse pressure (PP). Accordingly, when 
we substituted SBP and DBP with PP in our analyses, PP was 
significantly associated with changes in these parameters among 
women and men. In several epidemiological studies, PP has 
shown a superior predictive value compared with SBP or DBP 
alone.17 18 Higher PP is associated with elevated stress of the left 
ventricle which can result in ventricular hypertrophy and failure, 
critical determinants of LVDF.18
Metabolic factors
Previous cross-sectional studies have independently associated 
diastolic dysfunction with BMI and DM.19 In our study, DM was 
found to be strongly associated with worsening of LVDF param-
eters in men. Expanded myocardial fibrosis as well as accelerated 
apoptosis are among the pathophysiological features of diabetic 
cardiomyopathy.20 While several previous studies have shown 
larger deterioration of LVDF among diabetics,8 data regarding 
sex differences in the association of DM on LVDF are scarce and 
conflicting. Diabetes was found to be an independent contrib-
utor to LVM among women in the Framingham Heart Study21 
but among both women and men from the Cardiovascular 
Health Study22 and the Strong Heart Study.23
In our study, a larger association of BMI with worsening of 
LVDF over time was found among men than in women. The 
only prior, cross-sectional, study that evaluated sex differences 
of obesity on LVDF reported no association between BMI and 
LVDF indexes in women >65 years but did describe an associa-
tion between septal e’ and abdominal adiposity among younger 
women. Among men, BMI and abdominal obesity were asso-
ciated with a higher likelihood of diastolic dysfunction.24 The 
obesity-related mechanisms might be different for women and 
men. While for younger women, the effect of obesity might act 
Figure 3 The core findings of our study, showing the main risk factors associated with longitudinal changes in LVDF parameters among women and 
men. LVDF, left ventricular diastolic function.
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through its influence on SBP, the effect seems to be predomi-
nantly direct for men >65 years.24
smoking and lipid profile
Current smoking was only associated with a rise in DT among 
women in our study. Smoking commonly precedes the develop-
ment of HFpEF.25 While smoking confers a greater CHD risk 
in women compared with men,26 sex differences in the setting 
of HF have not been reported.27 Smoking has been suggested 
to significantly affect LVDF independently of its role as a risk 
factor for coronary atherosclerosis and through other indepen-
dent pathways.28
We found a favourable association of HDL cholesterol with 
diastolic function over time among women. Moreover, the use 
of lipid-lowering medication, as a proxy for chronic dyslipi-
daemia, was associated with worse LVDF over time. Previous 
cross-sectional studies have associated hyperlipidaemia with 
coronary endothelial dysfunction and with myocardial damage 
independent of ischaemia, leading to diastolic dysfunction.29 
Low levels of HDL cholesterol and elevated levels of total 
cholesterol are known risk factors for CHD and increasing LVM, 
both important factors leading to diastolic dysfunction. While 
increasing HDL levels have a more favourable effect in women 
compared with men, such gender differences in the association 
of HDL with LVDF require further study.
study strengths and limitations
Our study was based on a large group of women and men 
from a population-based cohort with repeated echocardio-
graphic examinations over 11 years of follow-up. The longi-
tudinal design allowed the use of linear mixed effect model to 
analyse progressive long-term alterations in continuous LVDF 
parameters. Availability of the well-defined set of covariates and 
detailed characterisation of the cohort allowed to examine LVDF 
parameters and their correlates from a gender-specific perspec-
tive. Nevertheless, limitations of our study also merit consider-
ation. The gold standard for diastolic function measurement is 
the pressure–volume relationship which is an invasive approach. 
However, Doppler measurements of mitral inflow and TDI 
allows for a valid non-invasive measurement of diastolic func-
tion.10 30 Echocardiography has proven to be a useful tool for 
assessing diastolic function, in order to minimise inherent limita-
tions operator-dependent, a standardised protocol was used by 
four trained echocardiographers with good inter-reader and 
intra-reader agreement.11 Our population included individuals 
of European ancestry. Therefore, the generalisability of our find-
ings to other ethnicities should be performed with caution. As 
inherited to all longitudinal cohort studies, survival bias cannot 
be entirely ruled out.
COnCLusIOns
In our large population-based study, women were found to 
have poorer diastolic function than men. However, age-re-
lated changes in continuous LVDF parameters were compa-
rable in both genders. Our findings highlight the correlates of 
asymptomatic diastolic dysfunction among women and men. 
The differential association of risk factors with LVDF among 
women and men could provide further hypothesis regarding 
the transition from a healthy heart to the development of 
HFpEF.5
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